First closing of our Series A round and onboarding of top biotech leaders to fuel our growth in 2022
Scailyte closes Series A financing round and onboards top biotech leaders to fuel our growth in 2022
Scailyte has successfully finished the first closing of their series A. Two new investors joined the round, and most of the existing shareholders engaged with follow-on investments. The second closing is planned for the first half of 2022 and Scailyte is currently in discussions with a number of additional investors.
Scailyte has set the focus on expanding the capabilities of its single-cell analytics platform, ScaiVision™. Moreover, the company is planning to establish further partnerships in the area of immuno-oncology. In addition, Scailyte is working on a custom solution to enable faster development of more robust cell therapies. For example, the solution will enhance quality assessment of the manufacturing product, among other applications in this field. In order to broaden its service offering, Scailyte is also seeking strategic partnerships among complementary AI-driven companies.
In 2021 Scailyte implemented an ISO:9001-compliant Quality Management System (QMS). The new QMS will be instrumental in the scale-up phase of the company and will help ensure the high quality of Scailyte’s discovery activities.
Over the course of 2021, Scailyte achieved great success in adding executive talent to its core team, the Board of Directors (BoD) and the Scientific Advisory Board (SAB).
Marco Ruella, MD joined the SAB in December 2021. He is an Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania.
Corinne Solier joined Scailyte in the COO position in November 2021. Formerly at Roche and a leader in the field of translational sciences, biomarkers and omics technologies, she is spearheading Scailyte’s discovery arm, the ScaiVision business unit. The new unit’s mission is to become Scailyte’s core discovery platform, leveraging clinical and molecular data integration, artificial intelligence and a network of clinical and industry partners. ScaiVision provides biomarker discovery and single-cell analytics services to precision medicine and immuno-oncology companies.
Corinne Solier: “Coming from the Pharma world, I have spent my career advancing precision medicine through efforts to understand the biology of diseases and to predict treatment response in the clinics, at the level of patient populations. I am convinced that the next revolution of precision medicine will be realised when we can fully harness the power of single-cell biological information to discover new and more sensitive biomarkers of diagnostic, predictive and prognostic value for individual patients. Scailyte’s perfectly suited capabilities, as well as the passionate and excellent team, convinced me to join the company, to fulfil our mission of advancing precision medicine”.
Anna Sumeray joined Scailyte’s BoD in November 2021. Anna is the CEO of Virometix, a University of Zurich spin-out company developing novel vaccines for the treatment and prevention of cancer and infectious diseases. She has over 20 years of experience in both large Pharma and start-up Biotechs and has held leadership roles in Business Development and General Management.
Anna Sumeray: “The Scailyte platform operates at the exciting interface of AI and Precision Medicine, and has a broad applicability across multiple therapeutic areas. There are so many possibilities to drive more targeted drug development and I am excited to work with the rest of the Board to help the company make the smartest strategic choices. I hope I can also connect Scailyte with partner companies and investors to help them leverage the value of their innovation.”
Investors and partners are welcome to connect with Scailyte via email:
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.
Recent News
Meet Scailyte at BioTechX
Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.
Recent News
Scailyte closes Series A funding with a CHF 6 million investment
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of
Recent News
VACANCY: Internship in Women’s Health R&D
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en
Recent News
Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Recent News
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
Meet Scailyte at BioTechX
Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.
Scailyte closes Series A funding with a CHF 6 million investment
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of
Recent News
VACANCY: Internship in Women’s Health R&D
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en
Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel